Company Filing History:
1 out of 1 
1 out of 832,912 Years Active: 2006-2008
Title: Innovations by Kenneth Stephen Albert
Introduction
Kenneth Stephen Albert is a notable inventor based in Mt. Kisco, NY (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled-release formulations of Diltiazem. With a total of 2 patents, his work focuses on improving the treatment of myocardial ischemia.
Latest Patents
Albert's latest patents include innovative methods for administering Diltiazem. One patent describes a method of treating or preventing myocardial ischemia through a controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem. This preparation is designed for evening dosing every 24 hours and contains between 180 mg to 420 mg of Diltiazem. It aims to provide a consistent concentration of Diltiazem in the blood between 10 to 17 hours after administration. The formulation exhibits higher bioavailability when taken at night compared to morning doses without food, adhering to FDA guidelines. Another patent outlines a similar controlled-release preparation, with dosages ranging from 120 mg to 540 mg, also focusing on sustained release and bioequivalence.
Career Highlights
Throughout his career, Kenneth has worked with various companies, including Biovall Laboratories International Srl. His expertise in pharmaceutical formulations has positioned him as a key player in the industry.
Collaborations
Some of his notable coworkers include Paul José Maes and Theophilus Jones Gana. Their collaborative efforts have contributed to advancements in pharmaceutical research and development.
Conclusion
Kenneth Stephen Albert's innovative work in controlled-release Diltiazem formulations showcases his commitment to improving patient care in cardiovascular health. His contributions continue to influence the pharmaceutical industry positively.